Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Medication adherence in randomized controlled trials evaluating cardiovascular or mortality outcomes in dialysis patients: A systematic review.

Murali KM, Mullan J, Chen JH, Roodenrys S, Lonergan M.

BMC Nephrol. 2017 Jan 31;18(1):42. doi: 10.1186/s12882-017-0449-1.

2.

Vascular calcification: When should we interfere in chronic kidney disease patients and how?

Sharaf El Din UA, Salem MM, Abdulazim DO.

World J Nephrol. 2016 Sep 6;5(5):398-417. doi: 10.5527/wjn.v5.i5.398. Review.

3.

Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.

Patel L, Bernard LM, Elder GJ.

Clin J Am Soc Nephrol. 2016 Feb 5;11(2):232-44. doi: 10.2215/CJN.06800615. Review.

4.

Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis.

Parfrey PS, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Chertow GM.

Clin J Am Soc Nephrol. 2016 Mar 7;11(3):539-46. doi: 10.2215/CJN.06370615. Review.

5.

Polymeric drugs: Advances in the development of pharmacologically active polymers.

Li J, Yu F, Chen Y, Oupický D.

J Control Release. 2015 Dec 10;219:369-82. doi: 10.1016/j.jconrel.2015.09.043. Review.

6.

Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.

Bover J, Ureña P, Ruiz-García C, daSilva I, Lescano P, del Carpio J, Ballarín J, Cozzolino M.

Clin J Am Soc Nephrol. 2016 Jan 7;11(1):161-74. doi: 10.2215/CJN.01760215. Review.

7.

Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis.

Gros B, Galán A, González-Parra E, Herrero JA, Echave M, Vegter S, Tolley K, Oyagüez I.

Health Econ Rev. 2015 Dec;5(1):49. doi: 10.1186/s13561-015-0049-3.

8.

From Phosphaturia to Cardiovascular Protection: Is Fibroblast Growth Factor-23 the Heart of the Matter?

Toto RD.

Circulation. 2015 Jul 7;132(1):7-9. doi: 10.1161/CIRCULATIONAHA.115.017177. No abstract available.

9.

Management of hyperphosphataemia in chronic kidney disease-challenges and solutions.

Ketteler M, Wüthrich RP, Floege J.

Clin Kidney J. 2013 Apr;6(2):128-36. doi: 10.1093/ckj/sfs173. Review.

10.

Clinical management of disturbances of calcium and phosphate metabolism in dialysis patients.

Eddington H, Heaf JG.

NDT Plus. 2009 Aug;2(4):267-72. doi: 10.1093/ndtplus/sfp044.

11.

The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Parfrey PS, Drüeke TB, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Kubo Y, Dehmel B, Goodman WG, Chertow GM; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators..

Clin J Am Soc Nephrol. 2015 May 7;10(5):791-9. doi: 10.2215/CJN.07730814.

12.

The demise of calcium-based phosphate binders-is this appropriate for children?

Rees L, Shroff R.

Pediatr Nephrol. 2015 Dec;30(12):2061-71. doi: 10.1007/s00467-014-3017-y. Review.

13.

Considerations and challenges in defining optimal iron utilization in hemodialysis.

Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP, Fishbane S; Dialysis Advisory Group of the American Society of Nephrology..

J Am Soc Nephrol. 2015 Jun;26(6):1238-47. doi: 10.1681/ASN.2014090922. Review.

14.

Recent advances in the management of hemodialysis patients: a focus on cardiovascular disease.

Jablonski KL, Chonchol M.

F1000Prime Rep. 2014 Aug 1;6:72. doi: 10.12703/P6-72. Review.

15.

Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder.

Goto S, Komaba H, Fukagawa M, Nishi S.

Kidney Int Suppl (2011). 2013 Dec;3(5):457-461. Review.

16.

Are there ways to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease?

Vo TM, Disthabanchong S.

World J Cardiol. 2014 May 26;6(5):216-26. doi: 10.4330/wjc.v6.i5.216. Review.

17.
18.

Patient satisfaction with in-centre haemodialysis care: an international survey.

Palmer SC, de Berardis G, Craig JC, Tong A, Tonelli M, Pellegrini F, Ruospo M, Hegbrant J, Wollheim C, Celia E, Gelfman R, Ferrari JN, Törok M, Murgo M, Leal M, Bednarek-Skublewska A, Dulawa J, Strippoli GF.

BMJ Open. 2014 May 19;4(5):e005020. doi: 10.1136/bmjopen-2014-005020.

19.

Calcium balance and negative impact of calcium load in peritoneal dialysis patients.

Wang AY.

Perit Dial Int. 2014 Jun;34(4):345-52. doi: 10.3747/pdi.2013.00177. Review.

20.

Comparative effectiveness of calcium acetate and sevelamer on clinical outcomes in elderly hemodialysis patients enrolled in Medicare part D.

Yusuf AA, Weinhandl ED, St Peter WL.

Am J Kidney Dis. 2014 Jul;64(1):95-103. doi: 10.1053/j.ajkd.2013.11.015.

Supplemental Content

Support Center